Zogenix Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
327
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.9B
Zogenix General Information
Description
Developer of therapeutic drugs and medicines intended to improve the lives of patients suffering from rare diseases. The company focuses on developing and commercializing treatments for central nervous system disorders and epilepsy, thereby addressing significant unmet medical needs.
Contact Information
Website
www.zogenix.comCorporate Office
- 5959 Horton Street
- Fifth Floor
- Emeryville, CA 94608
- United States
Corporate Office
- 5959 Horton Street
- Fifth Floor
- Emeryville, CA 94608
- United States
Zogenix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 07-Mar-2022 | $1.9B | Completed | Generating Revenue | ||
| 13. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 12. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 11. Debt - General | 16-Jun-2016 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | 01-Dec-2015 | Completed | Generating Revenue | |||
| 9. 2PO | 29-Jul-2015 | Completed | Generating Revenue | |||
| 8. 2PO | 05-Nov-2013 | Completed | Clinical Trials - Phase 3 | |||
| 7. 2PO | 15-Sep-2011 | Completed | Clinical Trials - Phase 3 | |||
| 6. IPO | 23-Nov-2010 | $56M | $245M | Completed | Clinical Trials - Phase 3 | |
| 5. Later Stage VC (Series C) | 14-Jul-2010 | $50M | $189M | Completed | Startup |
Zogenix Comparisons
Industry
Financing
Details
Zogenix Competitors (45)
One of Zogenix’s 45 competitors is US WorldMeds, a Formerly VC-backed company based in Louisville, KY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| US WorldMeds | Formerly VC-backed | Louisville, KY | ||||
| Sentynl Therapeutics | Formerly PE-Backed | Solana Beach, CA | ||||
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ | ||||
| Ethypharm | Private Equity-Backed | Saint Cloud, France | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY |
Zogenix Patents
Zogenix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3222484-A1 | Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools | Pending | 18-Jun-2021 | ||
| CA-3209159-A1 | Aqueous solutions containing purines and pyrimidines and uses thereof | Pending | 26-Mar-2021 | ||
| CA-3150755-A1 | Polymorphic forms of deoxycytidine, compositions comprising the same and uses | Pending | 19-Aug-2019 | ||
| CA-3096264-A1 | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools | Pending | 12-Apr-2018 | ||
| WO-2016137665-A1 | Needle-free injectors comprising sound suppression | Inactive | 27-Feb-2015 | A61M5/30 |
Zogenix Signals
Zogenix Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Avoro Capital | Venture Capital | Minority | ||
| Chicago Growth Partners | PE/Buyout | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Great Point Partners | PE/Buyout | Minority |
Zogenix Investments & Acquisitions (3)
Zogenix’s most recent deal was a Corporate with Tevard Biosciences for . The deal was made on 03-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tevard Biosciences | 03-Dec-2020 | Corporate | Drug Discovery | ||
| Modis Therapeutics | 09-Sep-2019 | Merger/Acquisition | Drug Discovery | ||
| Brabant Pharma | 27-Oct-2014 | Merger/Acquisition | Drug Delivery |
Zogenix ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
15.3 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Zogenix FAQs
-
When was Zogenix founded?
Zogenix was founded in 2006.
-
Where is Zogenix headquartered?
Zogenix is headquartered in Emeryville, CA.
-
What is the size of Zogenix?
Zogenix has 327 total employees.
-
What industry is Zogenix in?
Zogenix’s primary industry is Drug Discovery.
-
Is Zogenix a private or public company?
Zogenix is a Private company.
-
What is the current valuation of Zogenix?
The current valuation of Zogenix is .
-
What is Zogenix’s current revenue?
The current revenue for Zogenix is .
-
How much funding has Zogenix raised over time?
Zogenix has raised $465M.
-
Who are Zogenix’s investors?
Abingworth, Avoro Capital, Chicago Growth Partners, Domain Associates, and Great Point Partners are 5 of 12 investors who have invested in Zogenix.
-
Who are Zogenix’s competitors?
US WorldMeds, Sentynl Therapeutics, Johnson&Johnson Innovative Medicine, Ethypharm, and Attune Pharmaceuticals are some of the 45 competitors of Zogenix.
-
When was Zogenix acquired?
Zogenix was acquired on 07-Mar-2022.
-
Who acquired Zogenix?
Zogenix was acquired by UCB.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process